scholarly journals Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group

2021 ◽  
Author(s):  
Onder Cinar ◽  
Tahsin Turunc ◽  
Ilke Onur Kazaz ◽  
Omer Yildirim ◽  
Hasan Deliktas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prospective Study ◽  
Androgen Deprivation Therapy ◽  
Cognitive Functions ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation ◽  
Urological Surgery

scholarly journals Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group

2020 ◽  
Author(s):  
Onder Cinar ◽  
Tahsin Turunc ◽  
Ilke Onur Kazaz ◽  
Omer Yildirim ◽  
Hasan Deliktas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Depressive Symptoms ◽  
Androgen Deprivation Therapy ◽  
Cognitive Functions ◽  
Metastatic Prostate Cancer ◽  
Verbal Learning ◽  
Androgen Deprivation ◽  
California Verbal Learning Test ◽  
The Mean ◽  
Learning Test

Abstract Aims of the study: The aim of this study was to investigate the impact of testosterone deficiency on cognitive functions in metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). Methods: In this multicentric prospective study, 65 metastatic prostate cancer patients were evaluated. Demographic and clinical data were recorded. Cognitive functions were assessed using the Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test - Revised, and the Trail Making Test. Depressive symptoms were assessed using the Beck Depression Inventory. Cognitive functions and depressive symptoms were recorded before the androgen deprivation therapy and at the 3- and 6-month follow ups. Results: At the basal cognitive assessment, the mean Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test - Revised scores were 25.84 ± 17.54, 32.68 ± 10.60, and 17.63 ± 11.23, respectively, and the mean time for the Trail Making Test was 221.56 ± 92.44 s., and were similar at the 3-month, and 6-month controls (p > 0.05). The mean pretreatment, third and sixth month testosterone levels were 381.40 ± 157.53 ng/dL, 21.61 ± 9.09 ng/dL, and 12.25 ± 6.45 ng/dL (p < 0.05), and the total PSA levels were 46.46 ± 37.83 ng/mL, 1.41 ± 3.31 ng/mL, and 0.08 ± 0.14 ng/mL (p < 0.05), respectively. Conclusion: The ADT in patients with metastatic prostate cancer does not affect patients’ cognitive functions and depressive symptoms. However, further prospective randomized studies with higher cohorts and longer follow up periods are needed.

scholarly journals Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer

Cancer ◽  
2018 ◽  
Vol 125 (3) ◽  
pp. 453-462 ◽  
Author(s):  
Hala T. Borno ◽  
Daphne Y. Lichtensztajn ◽  
Scarlett L. Gomez ◽  
Nynikka R. Palmer ◽  
Charles J. Ryan
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation

A proposed link between spinal epidural lipomatosis, prostate cancer and androgen deprivation therapy

2017 ◽  
Vol 11 (4) ◽  
pp. 299-301 ◽  
Author(s):  
Isabel Tulloch ◽  
James T Laban ◽  
Andrew J Martin
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Spastic Paraparesis ◽  
Androgen Deprivation ◽  
Vertebral Metastases ◽  
Spinal Epidural Lipomatosis ◽  
Epidural Lipomatosis ◽  
Spinal Epidural

We present a patient with prostate cancer with vertebral metastases who developed spastic paraparesis secondary to spinal epidural lipomatosis (SEL) after receiving androgen deprivation therapy (ADT). We propose a link between ADT, metastatic prostate cancer and SEL.

Management of Metastatic Castrate-sensitive Prostate Cancer

2018 ◽  
Author(s):  
Derya Tilki ◽  
Marc A Dall’era ◽  
Christopher P Evans
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Survival Benefit ◽  
Metastatic Prostate Cancer ◽  
Oncologic Outcome ◽  
Standard Of Care ◽  
Abiraterone Acetate ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Treatment Paradigm

Oncologic outcome of patients with newly diagnosed metastatic prostate cancer (mPCa) is poor. The treatment paradigm for newly diagnosed mPCa has changed. The standard of care for men with metastatic hormone-naive prostate cancer has been systemic androgen deprivation therapy (ADT). Previous randomized studies demonstrated an overall survival benefit by the addition of early chemotherapy with six cycles of docetaxel. More recently, results from randomized trials also demonstrated a survival benefit by the addition of abiraterone acetate to the ADT in men with metastatic disease. The aim of this review is to summarize the results from most recent studies, including men with newly diagnosed metastatic hormone-naive prostate cancer, focusing on chemotherapy and ADT. This review contains 1 figure, 2 tables, and 47 references.  Key Words: abiraterone acetate, androgen deprivation therapy, androgen deprivation, castrate sensitive, chemotherapy, continuous androgen deprivation, docetaxel, hormone-naive, intermittent androgen deprivation, metastatic prostate cancer

Sign in / Sign up

Export Citation Format

Share Document